Sionna Therapeutics logo

Sionna Therapeutics

SION | NASDAQ
Chart Builder DCF Calculator
$3.12
-$0.21 (-6.31%)
At close: Nov 16, 2026, 4:00 PM ET
$3.11
-$0.01 (-0.33%)
After-hours: Nov 16, 2026, 6:53 PM ET
-6.31%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
24.6
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #937/1021 (Top 92%)

Key Statistics

Market Data

Market Cap $141.13M
1D Range
3.11 3.36
52W Range
3.10 51.04

Valuation (TTM)

PE -1.28
PB 0.59
EV/EBITDA 0.72

Valuation (NTM)

Forward PE N/A
Forward PEG -0.05
Price Target $7.00
Loading financial charts...

Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane ...

Sector Healthcare
Industry Biotechnology
Employees 59
IPO Date Feb 7, 2025
Fiscal Year January - December

Latest News

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks

3 months ago · benzinga.com

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

3 months ago · barrons.com

Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

3 months ago · seekingalpha.com

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript
Sionna Therapeutics Reports Second Quarter 2026 Financial Results

3 months ago · globenewswire.com

Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

5 months ago · seekingalpha.com

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

6 months ago · globenewswire.com

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
Sionna Therapeutics Reports First Quarter 2026 Financial Results

6 months ago · globenewswire.com

Sionna Therapeutics Reports First Quarter 2026 Financial Results
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

7 months ago · globenewswire.com

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

7 months ago · globenewswire.com

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

8 months ago · fool.com

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Analyst Summary

# of Analysts
8
Consensus
Hold
Price Target
$7.00
Upside
+124.36%
Buy (3)
Hold (4)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.